Jinarc

Tolvaptan, the active ingredient in Jinarc, is a vasopressin V2 receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of hyponatremia associated with euvolemic or hypervolemic states and for slowing disease progression in autosomal dominant polycystic kidney disease.

GNH USA supplies Jinarc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides reliable logistics for global distribution. This includes temperature‑controlled shipping where required to maintain product integrity.

Jinarc (tolvaptan) acts on the vasopressin V2 receptor pathway to manage disorders of water balance and cystic kidney disease.

- Hyponatremia (euvolemic or hypervolemic): helps raise serum sodium by promoting free water excretion. - Hyponatremia in heart failure: reduces fluid overload while correcting sodium levels. - Autosomal dominant polycystic kidney disease (ADPKD): slows cyst growth and preserves renal function.

Common Side Effects: - Thirst - Polyuria (increased urine output) - Dry mouth - Elevated serum sodium - Mild elevation of liver enzymes - Constipation

Serious or Rare Side Effects: - Severe hypernatremia - Hepatic injury or hepatitis - Dehydration leading to hypotension - Allergic reactions such as rash or angioedema

Before initiating therapy, clinicians should assess patient suitability and monitor key parameters. - Monitor serum sodium: avoid rapid correction to prevent osmotic demyelination. - Assess liver function: regular ALT/AST testing is recommended. - Evaluate renal function: use cautiously in patients with impaired kidney function. - Avoid use in hypovolemic patients: ensure adequate fluid status before treatment. - Store at below 25°C: keep in the original pack, protect from moisture.

Tolvaptan may interact with other medicines that affect its metabolism or fluid balance.

Major Interactions (Avoid): - Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin): increase tolvaptan exposure. - Strong CYP3A inducers (e.g., rifampin, carbamazepine): reduce therapeutic effect. - Concurrent V2 receptor antagonists (e.g., conivaptan): may cause additive aquaresis.

Moderate Interactions (Monitor Closely): - Diuretics: heightened risk of dehydration and electrolyte disturbances. - NSAIDs: may impair renal function when combined. - Lithium: increased risk of lithium toxicity. - ACE inhibitors or ARBs: monitor potassium and renal parameters.